Compliance with long-term oral hormonal replacement therapy

Maturitas. 1995 Sep;22(2):97-103. doi: 10.1016/0378-5122(95)00921-7.

Abstract

Objective: To study long-term compliance with oral hormonal replacement therapy (HRT).

Methods: A total of 151 early postmenopausal women were initially randomly allocated to three groups in a double-blind, placebo controlled trial. Fifty women received continuous combined therapy, another 50 were placed on sequential therapy, while the remaining 51 women were given placebo for 2 years with no subsequent therapy. After 2 years of the trial, the women were followed in an open investigation for a total of 8 years.

Results: After 8 years, 112 (85%) women were interviewed. None of the women in the combined group had changed to other therapies (46% were still in treatment), 32% were still being treated with sequential therapy and 18% had changed to other HRTs (mainly because the women disliked the monthly bleeding induced). Of the placebo group, 18% had started HRT while 53% still did not receive any therapy. Of the women who had taken combined therapy for 5 years, 95% were still in therapy at the 8-year stage. Of the 25 women who had taken sequential therapy for 5 years, 52% continued until the 8-year stage and a further 16% received other types of HRT. The women who changed HRT switched to continuous combined therapy.

Conclusion: The continuous combined treatment might provide an alternative to sequential treatment in postmenopausal women to achieve high long-term compliance.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Estradiol / administration & dosage
  • Estrogen Replacement Therapy*
  • Female
  • Humans
  • Long-Term Care
  • Norethindrone / administration & dosage
  • Norethindrone / analogs & derivatives
  • Norethindrone Acetate
  • Patient Compliance*
  • Progesterone / administration & dosage

Substances

  • Progesterone
  • Estradiol
  • Norethindrone Acetate
  • Norethindrone